A next-generation sequencing analysis of 1078 patients with NSCLC carrying KRAS mutations uncovered that 53.5% of the patients had additional mutations, including MET amplifications (15.4%), ERBB2 amplifications (13.8%), PIK3CA mutations (3.2%), EGFR mutations (1.2%) and BRAF mutations (1.3%) [33]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.